Short Answer
Complete Explanation
PI-RADS (Prostate Imaging Reporting and Data System) is a standardized reporting scheme for evaluating the prostate with multiparametric magnetic resonance imaging (mpMRI). A PI-RADS score of 4 denotes a moderate to high probability that a lesion corresponds to clinically significant prostate cancer, typically defined as Gleason grade group 2 or higher. The assessment integrates findings from T2‑weighted imaging, diffusion‑weighted imaging (DWI), and dynamic contrast‑enhanced (DCE) sequences according to the PI‑RADS v2.1 guidelines.
- Definition:
PI-RADS 4 indicates a lesion with a 30–80 % likelihood of being clinically significant cancer, warranting targeted biopsy. - Imaging Criteria:
Typical features include a focal lesion with marked hypointensity on T2‑weighted images, high signal on high‑b DWI (low ADC), and early enhancement on DCE, scoring 4 on the individual sequence Likert scales. - Clinical Management:
Patients with PI-RADS 4 lesions are generally recommended to undergo MRI‑targeted biopsy, often combined with systematic sampling, to confirm histology and guide treatment. - Comparison with Other Scores:
PI-RADS 3 is equivocal (intermediate risk), while PI-RADS 5 signifies a very high (>80 %) probability of significant cancer. - Limitations:
Inter‑observer variability and technical factors can affect scoring; a PI-RADS 4 does not guarantee cancer, nor does a lower score exclude it.
Common Misconceptions
PI-RADS 4 always means cancer is present.
It reflects a probability; biopsy is required for definitive diagnosis.
A PI-RADS 4 lesion requires immediate treatment.
Management decisions are based on biopsy results, patient age, comorbidities, and preferences.
The score is static across all MRI machines.
Image quality, field strength, and protocol adherence influence scoring consistency.
FAQ
What does a PI-RADS 4 score mean for a patient?
It means the MRI has identified a lesion with a moderate to high probability of clinically significant cancer, and a targeted biopsy is usually recommended to confirm the presence and grade of cancer.
How is PI-RADS 4 different from PI-RADS 3?
PI-RADS 3 is considered equivocal with an intermediate risk, while PI-RADS 4 carries a higher likelihood (30‑80 %) of significant cancer, prompting more definitive diagnostic steps.
Can a PI-RADS 4 lesion be benign?
Yes. Although the probability of cancer is elevated, PI-RADS 4 is not definitive; biopsy may reveal benign pathology or low‑grade disease.
Leave a Reply